Key Benefits 1, 2, 3, 4
1 Falagas ME, Vouloumanou EK, Samonis G, Vardakasa KZ. Fosfomycin. Clin Microbiol Rev 2016; 29: 321–347.
2 Pontikis K, Karaiskos I, Bastani S, Dimopoulos G, Kalogirou M, Katsiari M, Oikonomou A, Poulakou G, Roilides E, Giamarellou H. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents. 2014 Jan;43(1):52-9.
3 Putensen C, Ellger B, Sakka SG, Weyland A, Schmidt K, Zoller M, Weiler N, Kindgen-Milles D, Jaschinski U, Weile J, Lindau S, Kieninger M, Faltlhauser A, Jung N, Teschendorf P, Adamzik M, Gründling M, Wahlers T, Gerlach H, Litty FA. Current clinical use of intravenous fosfomycin in ICU patients in two European countries. Infection. 2019 Oct;47(5):827-836
4 Kaye KS, Rice LB, Dane A, Stus V, Sagan O, Fedosiuk E, Das A, Skarinsky D, Eckburg PB, Ellis-Grosse EJ. Fosfomycin for injection (ZTI-01) vs Piperacillin-Tazobactam (PIP-TAZ) for the Treatment of Complicated Urinary Tract Infection (cUTI) Including Acute Pyelonephritis (AP): ZEUS, A Phase 2/3 Randomized Trial. Clin Infect Dis. 2019 Mar 6. pii: ciz181. doi: 10.1093/cid/ciz181. [Epub ahead of print]